Medsafe is investigating a brand of oestrogen patches, after receiving multiple reports from users who say they are experiencing a lack of adhesion and efficacy. An Estradot user, Crystal, noticed her ...

Medsafe is investigating a brand of oestrogen patches, after receiving multiple reports from users who say they are ...

Find out what the stars predict for your love, career, health, and finances. Check remedies, lucky colour, and lucky number ...

StemWave shockwave therapy demonstrates success rates between 80-90% for chronic pain sufferers using acoustic wave technology The treatment effectively addresses joint pain, tendonitis, back pain, ...

The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...

(Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus placebo in patients with previously treated advanced ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen: ...

Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...

Fruquintinib plus sintilimab significantly improved PFS in advanced RCC patients compared to axitinib or everolimus, with a median PFS of 22.21 months versus 6.90 months. The combination therapy ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

Development of robotic device for pain and somatosensory assays in rodents allows remote, quantitative, and reproducible delivery of mechanical stimuli.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...